Type 2 low asthma in obese and non-obese patients treated with Tezepelumab
Latest Information Update: 06 Dec 2021
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms POTENT Trail
- 04 Dec 2021 Planned initiation date changed from 1 Dec 2021 to 1 Feb 2022.
- 25 Oct 2021 New trial record